Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02213055 · ClinicalTrials.gov registry record · Phase 2

Pediatric Head Lice Study Product Comparison

A Phase 2 study of Head Lice, sponsored by Hackensack Meridian Health.

Completed
Registry status
Phase 2
Development phase
97
Enrollment target
1
Study location

NCT02213055 is a Phase 2 study of Head Lice that has completed, run by Hackensack Meridian Health. The registered enrollment target is 97 participants, roughly in line with the 97-participant average among 5 other Head Lice trials with a reported enrollment target. The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02213055, a Phase 2 study of Head Lice, has completed, sponsored by Hackensack Meridian Health.

COMPLETED
Registry status
Phase 2
Development phase
97 participants
Enrollment target
1
Study location

Study Summary

* To evaluate the efficacy of LiceMD for the treatment of head lice in a pediatric population. * To evaluate the safety of LiceMD in a pediatric population.

Conditions Studied

Interventions

  • DRUG LICEMD
  • DRUG Standard Head lice product

Study Locations (1)

New Jersey

  • Hackensack University Medical Center - Hackensack

Trial Details

FieldValue
Enrollment Target 97 participants
Start Date 2009-05
Est. Completion 2014-08
Phase Phase 2

Sponsor

Hackensack Meridian Health

90 total trials

What the Registry Record Tells You About NCT02213055

The ClinicalTrials.gov registry entry for NCT02213055 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 97 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 97-participant average among 5 other Head Lice trials with a reported enrollment target. The listed sponsor is Hackensack Meridian Health, which has 90 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Head Lice appearing as the primary indexed condition, and to 2 interventions - of which LICEMD is the first listed.

NCT02213055 reports 1 study location spanning 1 distinct geographic area - top geographies include New Jersey.

Frequently Asked Questions

What is clinical trial NCT02213055 about?

NCT02213055 is a clinical study titled "Pediatric Head Lice Study Product Comparison". * To evaluate the efficacy of LiceMD for the treatment of head lice in a pediatric population. * To evaluate the safety of LiceMD in a pediatric population.

What is the current status of trial NCT02213055?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 97 participants. The study started on 2009-05. Estimated completion is 2014-08.

What conditions does trial NCT02213055 study?

This clinical trial studies the following conditions: Head Lice.

What interventions are being tested in trial NCT02213055?

The interventions under investigation include: LICEMD (DRUG), Standard Head lice product (DRUG).

Who is sponsoring clinical trial NCT02213055?

This trial is sponsored by Hackensack Meridian Health, which has 90 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02213055 being conducted?

This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Head Lice

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.